No bullshit | 100% garantie

Pas convaincu ?

Alors jette un oeil aux news précédentes.

AIX MARSEILLE METROPOLE FRENCH TECH will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use MailChimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to MailChimp for processing. Learn more about MailChimp's privacy practices here

Chiffre d'affaires
< 100 K€
Nombre de personnes
10 - 50
% CA international
Incubé / Accéleré


DORMES Elodie - Business Development Manager



Le Pitch

VECT-HORUS has developed a technology platform, VECTrans®, that facilitates the targeting and delivery of drugs or imaging agents into the brain through the Blood-Brain Barrier (BBB) and to tumors which overexpressed the specific targeted receptors (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need.

VECT-HORUS discovered, validated and optimized a family of vector molecules that target the LDL receptor and that allow drug delivery to different organs. The vectors are protected by several families of patents and ongoing patent applications. The vectors have different properties (structure, affinity, stability, organ specificity) allowing adaptation of the vectorization process on a case to case basis.
The expression of LDLR in several organs and in cancer cells opens opportunities for the delivery of therapeutic or imaging molecules in liver and adrenal glands for instance, to the brain, to tumors and in lysosomal storage diseases.
VECT-HORUS’ partnering strategy is based on out-licensing of its technology, of its vectors and vector-drug conjugates.

Autres startups dans les même domaines d’activités